ABIGAIL BECK: Open Payments
NPI 1306245360 · ASHLAND, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$360 in 19 payments from 9 companies in 2025. Trend: 2023 $499 · 2024 $342 · 2025 $360
Food & beverage: $360
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $83 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| ABBVIE INC. | 2 | $33 |
| Dexcom, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $20 |
| SANOFI-AVENTIS U.S. LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
Products named: TRELEGY ELLIPTA, Wegovy, CAPLYTA, VRAYLAR, Dexcom G6 Transmitter, BREZTRI, REXULTI, AIRSUPRA.
Industry payments across KY — which companies pay providers there.
